Does Immediate Breast Reconstruction after Mastectomy affect the Initiation of Adjuvant Chemotherapy?.
10.4048/jbc.2011.14.4.322
- Author:
Jeonghui LEE
1
;
Se Kyung LEE
;
Sangmin KIM
;
Min Young KOO
;
Min Young CHOI
;
Soo Youn BAE
;
Dong Hui CHO
;
Jiyoung KIM
;
Seung Pil JUNG
;
Jun Ho CHOE
;
Jung Han KIM
;
Jee Soo KIM
;
Jeong Eon LEE
;
Jung Hyun YANG
;
Seok Jin NAM
Author Information
1. Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. jeongeon.lee@samsung.com
- Publication Type:Original Article
- Keywords:
Adjuvant chemotherapy;
Breast neoplasms;
Breast reconstruction
- MeSH:
Breast;
Breast Neoplasms;
Chemotherapy, Adjuvant;
Diclofenac;
Electronics;
Electrons;
Female;
Humans;
Mammaplasty;
Mastectomy;
Retrospective Studies
- From:Journal of Breast Cancer
2011;14(4):322-327
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The frequency of immediate breast reconstruction (IBR) is increasing, and the types of reconstruction used are diverse. Adjuvant chemotherapy is a life-saving intervention in selected high-risk breast cancer patients. The aim of our study was to determine how IBR and type of reconstruction affect the timing of the initiation of chemotherapy. METHODS: We obtained data from female breast cancer patients treated by mastectomy with IBR (IBR group) and without IBR (mastectomy only group) who received adjuvant chemotherapy between January 1, 2008, and December 31, 2010. We retrospectively collected data including patient characteristics, disease characteristics, treatment details, and treatment outcomes from our institutional electronic patient database and medical treatment records. The reconstruction types were categorized as deep inferior epigastric perforator (DIEP) flap, latissimus dorsi (LD) flap and tissue expander/implant (TEI). RESULTS: In total, 595 patients were included in this study. Of these patients, 43 underwent mastectomy with IBR (IBR group) and 552 patients did not undergo reconstruction (mastectomy only group). There was significant difference in the timing of the initiation of chemotherapy between the two groups (p<0.0001). There were no cases of delays of more than 12 weeks. In the IBR group, 20 patients received TEI, 9 patients were treated by the insertion DIEP flaps, and 14 patients were treated by LD flaps. There were no significant differences in the timing of chemotherapy according to the type of reconstruction (p=0.095). CONCLUSION: IBR delays the initiation of chemotherapy, but does not lead to omission or significant clinical delay in chemotherapy. Further, the type of reconstruction does not affect the timing of chemotherapy.
